Controlled release of hepatocyte growth factor from gelatin hydrogels based on hydrogel degradation.
This paper investigates the controlled release of hepatocyte growth factor (HGF) by biodegradable gelatin hydrogels and their HGF-induced angiogenic effect. Hydrogels of different degradabilities were prepared through chemical crosslinking gelatin with varied amounts of glutaraldehyde. When the gelatin hydrogels were radioiodinated and subcutaneously implanted into the back of mice, the remaining radioactivity of the hydrogels decreased with time. However, the remaining period became longer when the concentration of glutaraldehyde used for hydrogel preparation increased. Following implantation of gelatin hydrogels incorporating 125I-labeled HGF, the HGF radioactivity retained in the mouse subcutis for longer time periods as the glutaraldehyde concentration becomes higher. The time profile of HGF remaining in every gelatin hydrogel was in good accordance with that of hydrogel degradation, indicating HGF release as a result of hydrogel biodegradation. The gelatin hydrogel incorporating HGF histologically induced angiogenic change around the implanted hydrogel. Gelatin hydrogels incorporating 5 and 10 microg HGF significantly enhanced the number of capillaries newly formed around the implanted site. This was in marked contrast to free HGF of same dose form and HGF-free, empty gelatin hydrogel. The gelatin hydrogel incorporating HGF induced VEGF around the implanted site. In vitro bioassay revealed that HGF molecules interacting with gelatin, still exhibited the biological activity. The interacted HGF would be released from gelatin hydrogels only when they were degraded to generate water-soluble gelatin fragments. It is possible that the HGF associating gelatin fragments of bioactivating, results in induced angiogenic effect.
Ozeki
M
M
Institute for Frontier Medical Sciences, Kyoto University, Japan.
Ishii
T
T
Hirano
Y
Y
Tabata
Y
Y
D000818:Animals; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004337:Drug Carriers / Q000008:administration & dosage / Q000378:metabolism; D005780:Gelatin / Q000008:administration & dosage / Q000378:metabolism*; D017228:Hepatocyte Growth Factor / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000494:pharmacology; D020100:Hydrogels / Q000008:administration & dosage / Q000378:metabolism*; D007457:Iodine Radioisotopes; D051379:Mice; D008853:Microscopy; D018919:Neovascularization, Physiologic / Q000187:drug effects; D013194:Staining and Labeling; D013997:Time Factors
D003692:Delayed-Action Preparations; D004337:Drug Carriers; D020100:Hydrogels; D007457:Iodine Radioisotopes; D017228:Hepatocyte Growth Factor; D005780:Gelatin